Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis

References

• Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2021;17:327–406.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203. http://www.sciencedirect.com/science/article/pii/S1734114014002886.
   PubMed Web of Science ®Google Scholar
• Barber RC. The genetics of Alzheimer’s disease. Lao O, Chagnon Y, Castro JA, et al., editors. Scientifica (Cairo). 2012;2012:246210.
   PubMedGoogle Scholar
• DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease.Mol Neurodegener. 2019;14(1):1–18.
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 2019;cited 2021 Oct 12 1112 DOI: 10.15252/emmm.201911170.
   PubMedGoogle Scholar
• Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80(6):1347–1358.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science(80-) 1992;256:184–185.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, and Bendlin BB. Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26(1):296–308.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem Elsevier Masson S R L. 2021;216:113320.
   PubMed Web of Science ®Google Scholar
• Current treatments, Alzheimer’s & Dementia | research Center | Alzheimer’s association [Internet]. cited 2016 May 23]. Available from 2016 May 23: http://www.alz.org/research/science/alzheimers_disease_treatments.asp.
   Google Scholar
• Aduhelm | ALZFORUM [Internet]. cited 2021 Jun 18]. Available from 2021 Jun 18: https://www.alzforum.org/therapeutics/aduhelm.
   Google Scholar
• Cohen AD, Landau SM, Snitz BE, et al. Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease [Internet]. Mol Cell Neurosci. 2019;97:3–17. Academic Press Inc.
   PubMedGoogle Scholar
• Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;18–33. https://pubmed.ncbi.nlm.nih.gov/30529601/.
   PubMedGoogle Scholar
• Lee JC, Kim SJ, Hong S, et al. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers [Internet]. Exp. Mol. Med. Nature Publishing Group; 2019 cited 2021 Jun 23]. Available from 2021 Jun 23: /pmc/articles/PMC6509326/.
   Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework [Internet]. Clin. Pharmacol. Ther. Clin Pharmacol Ther; 2001 [cited 2021 Jun 23]. p. 89–95. Available from: https://pubmed.ncbi.nlm.nih.gov/11240971/.
   Google Scholar
• Khoury R, and Ghossoub E. Diagnostic biomarkers of Alzheimer’s disease: a state-of-the-art review. Biomarkers Neuropsychiatry. 2019;1:100005.
   Google Scholar
• Baldacci F, Mazzucchi S, and Della Vecchia A, et al. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Rev Mol Diagn. 2020;20(4):421–441.
   PubMed Web of Science ®Google Scholar
• Thies B, Truschke E, Morrison-Bogorad M, et al. Consensus report of the working group on: molecular and biochemical markers of Alzheimer’s disease. Neurobiol Aging. 1999;20(2):247.
   PubMedGoogle Scholar
• Dubois B, Villain N, and Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group. Lancet Neurol. 2021;20(6):484–496.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, and Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–562. Internet.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):263–269.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease [Internet]. Alzheimer’s Dement. Elsevier Inc; 2018 [cited 2021 Jun 23]. p. 1505–1521. Available from: https://pubmed.ncbi.nlm.nih.gov/30316776/.
   Google Scholar
• Cummings J, Lee G, Zhong K, et al. Alzheimer’s disease drug development pipeline: 2021. Alzheimer’s Dement Transl Res Clin Interv. 2021;cited 2021 Sep 19; 7:e12179. Internet https://onlinelibrary.wiley.com/doi/full/10.1002/trc2.12179.
   PubMedGoogle Scholar
• Lang FM, Mo Y, Sabbagh M, et al. Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled, phase 3 clinical trial (MINDSET). Alzheimer’s Dement Transl Res Clin Interv. 2021;7:e12136. https://onlinelibrary.wiley.com/doi/full/10.1002/trc2.12136.
   PubMedGoogle Scholar
• Rosenberg PB, Drye LT, Porsteinsson AP, et al. Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatrics. 2015;27(12):2059–2067. Available from
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Verberk IMW, and Thijssen EH, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.
   PubMed Web of Science ®Google Scholar
• Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain Internet]. 2021 144:325–339. Available from.;(1)
   PubMedGoogle Scholar
• Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020 [cited 2021 Sep 19];324(8):772–781. Internet: https://jamanetwork.com/journals/jama/fullarticle/2768841.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament Light And Neurodegeneration In Patients With Alzheimer disease. JAMA Neurol. 2019 [cited 2021 Sep 19];76(7):791–799. Internet: https://jamanetwork.com/journals/jamaneurology/fullarticle/2731440.
   PubMed Web of Science ®Google Scholar
• Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s Dement [Internet]. 2017 [cited 2021 Aug 6];13(8):841–849. Available from: https://alzjournals.onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2017.06.2266
   PubMed Web of Science ®Google Scholar
• Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and P-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol Internet]. 2011;68:1137–1144. Available from.;(9)
   PubMedGoogle Scholar
• Janelidze S, Zetterberg H, Mattsson N, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154–165.
   PubMed Web of Science ®Google Scholar
• Willemse EAJ, van Maurik IS, Tijms BM, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2018;10:563–572.
   PubMedGoogle Scholar
• Budelier MM, Bateman RJ. Biomarkers of Alzheimer disease. J Appl Lab Med. 2020;5(1):194–208.
   PubMedGoogle Scholar
• Alcolea D, Pegueroles J, Muñoz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815. Internet
   PubMed Web of Science ®Google Scholar
• Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer’s Dement. 2018;14(11):1460–1469.
   PubMed Web of Science ®Google Scholar
• Korecka M, Waligorska T, Figurski M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-β 42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimer’s Dis. 2014;41(2):441–451.
   PubMedGoogle Scholar
• Pannee J, Portelius E, Minthon L, et al. Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET. J Neurochem. 2016 [cited 2022 Mar 18];139(4):651–658. https://onlinelibrary.wiley.com/doi/full/10.1111/jnc.13838
   PubMed Web of Science ®Google Scholar
• Leinenbach A, Pannee, Dülffer T, et al. Mass spectrometry–based candidate reference measurement procedure for quantification of Amyloid-β in cerebrospinal fluid. Clin Chem. 2014;60(7):987994. Internet
   Google Scholar
• Moon S, Kim S, Mankhong S, et al. Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans. Alzheimer’s Res Ther. 2021;13:1–12. Internet: https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00767-3
   PubMedGoogle Scholar
• Leitão MJ, Silva-Spínola A, Santana I, et al. Clinical validation of the lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease. Alzheimer’s Res Ther. 2019;11:1–12. 111: https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0550-8
   PubMedGoogle Scholar
• Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimer’s Res Ther. 2019;11:1–15. 111: https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0485-0
   PubMedGoogle Scholar
• Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal fluid Aβ 42/40 corresponds better than Aβ 42 to amyloid PET in Alzheimer’s disease. J Alzheimer’s Dis. 2017;55(2):813–822.
   PubMedGoogle Scholar
• Mattsson N, Palmqvist S, Stomrud E, et al. Staging β-amyloid pathology with amyloid positron emission tomography. JAMANeurol. 2019;76(11):1319–1329.
   Google Scholar
• Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65(8):1102–1107.
   PubMedGoogle Scholar
• Mulder SD, van der Flier WM, Verheijen JH, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimer’s Dis. 2010;20(1):253–260.
   PubMedGoogle Scholar
• Zhong Z, Ewers M, Teipel S, et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007;64(6):718–726.
   PubMedGoogle Scholar
• Perneczky R, Alexopoulos P Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer’s disease. Alzheimer’s Dement. 2014;10(5S):S425–S429.e1. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2013.09.006.
   PubMedGoogle Scholar
• Savage MJ, Holder DJ, Wu G, et al. Soluble BACE-1 activity and sAβPPβ concentrations in Alzheimer’s disease and age-matched healthy control cerebrospinal fluid from the Alzheimer’s disease neuroimaging initiative-1 baseline cohort. J Alzheimers Dis. 2015;46(2):431. Internet
   PubMed Web of Science ®Google Scholar
• Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimer’s Dis. 2011;26(4):627–645.
   PubMedGoogle Scholar
• Yuan Y, Gu ZX, Wei WS Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol. 2009;30(2):404–410. www.ajnr.org.
   PubMedGoogle Scholar
• Sanchez-Catasus C A, Stormezand G N, van Laar P J, et al. FDG-PET for prediction of AD dementia in mild cognitive impairment. a review of the state of the art with particular emphasis on the comparison with other neuroimaging modalities (MRI and perfusion SPECT). Curr Alzheimer Res. 2017;14(2):127–142.
   PubMedGoogle Scholar
• Marcus C, Mena E, Subramaniam RM Brain PET in the diagnosis of Alzheimer’s disease [Internet]. Clin. Nucl. Med. Lippincott Williams and Wilkins; 2014p. e413–e426. /pmc/articles/PMC4332800/.
   Google Scholar
• O’Brien JT, Herholz K Amyloid imaging for dementia in clinical practice. BMC Med. 2015;13(1):1–3. http://www.alz.co.uk/sites/default/files/national-.
   PubMedGoogle Scholar
• Zhang S, Smailagic N, Hyde C, et al. 11C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) [Internet]. Cochrane Database Syst. Rev. John Wiley and Sons Ltd; 2014 /pmc/articles/PMC6464750/.
   Google Scholar
• Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;11:CD012216.
   PubMedGoogle Scholar
• Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetaben for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) [Internet]. Cochrane Database Syst. Rev. John Wiley and Sons Ltd; 2017 cited 2021 Jul 1]. Available from 2021 Jul 1: pmc/articles/PMC6485979/.
   Google Scholar
• Müller EG, Edwin TH, Stokke C, et al. Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic. PLoS One. 2019;14(8):e0221365.
   PubMedGoogle Scholar
• Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimer’s Dement. 2019;15(8):1071–1080.
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–684.
   PubMed Web of Science ®Google Scholar
• Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122(4):401–413.
   PubMed Web of Science ®Google Scholar
• Rembach A, Faux NG, Watt AD, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimer’s Dement. 2014;10(1):53–61.
   PubMed Web of Science ®Google Scholar
• Hanon O, Vidal JS, Lehmann S, et al. Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers. Alzheimer’s Dement. 2018;14(7):858–868.
   PubMedGoogle Scholar
• Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6(1). DOI: 10.1038/srep26801.
   PubMedGoogle Scholar
• Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648–658.
   PubMed Web of Science ®Google Scholar
• Wennström M, Surova Y, Hall S, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer’s but not Parkinson’s disease or dementia with lewy bodies. PLoS One. 2015;10(8):e0135458.
   PubMed Web of Science ®Google Scholar
• Walker JM. p53 protocols - IN M OLECULAR B IOLOGY TM series editor. Life Sci. 2009;531:588.
   Google Scholar
• Arbaciauskaite M, Lei Y, Cho YK. High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples. Antib Ther. 2021;4(1):34–44.
   PubMedGoogle Scholar
• Yang S-Y, Chiu M-J, Chen T-F, et al. Detection of plasma biomarkers using immunomagnetic reduction: a promising method for the early diagnosis of Alzheimer’s disease. Neurol Ther. 2017;6(S1):37–56.
   PubMedGoogle Scholar
• Green AJE RT-QuIC: a new test for sporadic CJD. Pract Neurol. 2019;19(1):49–55. https://pn.bmj.com/content/19/1/49.
   PubMedGoogle Scholar
• Del PE, Beatino MF, and Campese N, et al. Fluid candidate biomarkers for Alzheimer’s disease: a precision medicine approach. J Pers Med. 2020;10(4):221.
   Google Scholar
• Candelise N, Baiardi S, and Franceschini A, et al. Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. Acta Neuropathol Commun. 2020;8(1):1–16.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Mol Neurodegener. 2021;16(1):1–7.
   PubMedGoogle Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–254.
   PubMed Web of Science ®Google Scholar
• Li Q, Berndt M, Bush A, et al. Membrane-associated forms of the βA4 amyloid protein precursor of Alzheimer’s disease in human platelet and brain: surface expression on the activated human platelet. Blood. 1994;84(1):133–142.
   PubMedGoogle Scholar
• Ashton NJ, Ide M, Zetterberg H, et al. Salivary biomarkers for Alzheimer’s disease and related disorders. Neurol Ther. 201982;8(S2):83–94.
   PubMedGoogle Scholar
• van Wijngaarden P, Hadoux X, Alwan M, et al. Emerging ocular biomarkers of Alzheimer disease. Clin Experiment Ophthalmol. 2017;45(1):54–61.
   PubMedGoogle Scholar
• Stix B, Leber M, Bingemer P, et al. Hereditary lattice corneal dystrophy is associated with corneal amyloid deposits enclosing C-terminal fragments of keratoepithelin. Invest Ophthalmol Vis Sci. 2005;46(4):1133–1139.
   PubMedGoogle Scholar
• Prakasam A, Muthuswamy A, Ablonczy Z, et al. Differential accumulation of secreted AβPP metabolites in ocular fluids. J Alzheimer’s Dis. 2010;20(4):1243–1253.
   PubMed Web of Science ®Google Scholar
• Örnek N, Dağ E, Örnek K. Corneal sensitivity and tear function in neurodegenerative diseases. Current Eye Research. 2015;40 423–428. Available from 4
   PubMed Web of Science ®Google Scholar
• Mancino R, Martucci A, Cesareo M, et al. Glaucoma and Alzheimer disease: one age-related neurodegenerative disease of the brain. Curr Neuropharmacol. 2018;16(7):971.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome. J Proteomics. 2012;75(13):3877–3885.
   PubMed Web of Science ®Google Scholar
• Frost S, Kanagasingam Y, Sohrabi H, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl Psychiatry. 2013;3(2):e233–e233.
   PubMedGoogle Scholar
• Feke GT, Hyman BT, Stern RA, et al. Retinal blood flow in mild cognitive impairment and Alzheimer’s disease. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2015;1:144. /pmc/articles/PMC4876882/.
   PubMedGoogle Scholar
• Parisi V, Restuccia R, Fattapposta F, et al. Morphological and functional retinal impairment in Alzheimer’s disease patients. Clin Neurophysiol. 2001;112(10):1860–1867.
   PubMed Web of Science ®Google Scholar
• Kesler A, Vakhapova V, Korczyn AD, et al. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg. 2011;113(7):523–526.
   PubMed Web of Science ®Google Scholar
• Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017;2(16). DOI: 10.1172/jci.insight.93621.
   PubMed Web of Science ®Google Scholar
• Ganmor E, Segev R, Schneidman E The architecture of functional interaction networks in the retina. J Neurosci. 2011;31(8):3044–3054. https://www.jneurosci.org/content/31/8/3044.
   PubMedGoogle Scholar
• Masland RH. The neuronal organization of the Retina. Neuron. 2012;76(2):266–280.
   PubMed Web of Science ®Google Scholar
• London A, Benhar I, Schwartz M The retina as a window to the brain - From eye research to CNS disorders [Internet]. Nat. Rev. Neurol. Nat Rev Neurol; 2013. p. 44–53. https://pubmed.ncbi.nlm.nih.gov/23165340/.
   Google Scholar
• Schaffer C, Sarad N, DeCrumpe A, et al. Biomarkers in the diagnosis and prognosis of Alzheimer’s disease.2014;20:589–600. Available from.Journal of Laboratory Automation5:
   PubMedGoogle Scholar
• Zetterberg H Review: tau in biofluids – relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol. 2017;43(3):194–199. https://onlinelibrary.wiley.com/doi/full/10.1111/nan.12378.
   PubMed Web of Science ®Google Scholar
• Willemse EAJ, van Maurik IS, Tijms BM, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2018;10:563–572. https://pubmed.ncbi.nlm.nih.gov/30406175/.
   PubMedGoogle Scholar
• Lifke V, Kollmorgen G, Manuilova E, et al. Elecsys® total-tau and phospho-tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem. 2019;72:30–38.
   PubMedGoogle Scholar
• Sato C, Barthélemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284–1298.e7.
   PubMed Web of Science ®Google Scholar
• Sato C, Barthélemy NR, Mawuenyega KG, et al. Erratum: tau kinetics in neurons and the human central nervous system neuron. 2018;976:Neuron. Cell Press 861–864.https://profiles.wustl.edu/en/publications/erratum-tau-kinetics-in-neurons-and-the-human-central-nervous-sys.
   Google Scholar
• Barthélemy NR, Mallipeddi N, Moiseyev P, et al. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. Extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer’s disease. Front Aging Neurosci Internet]. 2019 cited 2021 Jun 30;11:121. Available from
   PubMed Web of Science ®Google Scholar
• McAvoy T, Lassman ME, Spellman DS, et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin Chem. 2014;60(4):683–689.
   PubMed Web of Science ®Google Scholar
• Chiasserini D, Biscetti L, Farotti L, et al. Performance evaluation of an automated ELISA system for Alzheimer’s disease detection in clinical routine. J Alzheimer’s Dis. 2016;54(1):55–67.
   PubMedGoogle Scholar
• Arora H, Ramesh M, and Rajasekhar K, et al. Molecular tools to detect alloforms of Aβ and Tau: implications for multiplexing and multimodal diagnosis of Alzheimer’s disease. Bull Chem Soc Jpn. 2020;93(4):507–546.
   Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jangili P, and Son S, et al. Fluorescent diagnostic probes in neurodegenerative diseases. Adv Mater. 2020;32:2001945. https://onlinelibrary.wiley.com/doi/full/10.1002/adma.202001945.
   Google Scholar
• Maia LF, Kaeser SA, Reichwald J, et al. Changes in amyloid-β and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5(194) DOI: 10.1126/scitranslmed.3006446.
   PubMedGoogle Scholar
• Tariciotti L, Casadei M, Honig LS, et al. Clinical experience with cerebrospinal fluid Aβ 42, total and phosphorylated tau in the evaluation of 1,016 individuals for suspected dementia. J Alzheimer’s Dis. 2018;65(4):1417–1425.
   PubMedGoogle Scholar
• Fossati S, Cejudo JR, Debure L, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer’s disease. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2019;11:483. /pmc/articles/PMC6624242/.
   PubMedGoogle Scholar
• Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827–1835.
   PubMed Web of Science ®Google Scholar
• Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76(5):598–606.
   PubMed Web of Science ®Google Scholar
• Mielke MM, Hagen CE, Wennberg AMV, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging. JAMA Neurol. 2017;74(9):1073–1080.
   PubMedGoogle Scholar
• Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol Neurodegener. 2017;12(1):1–11. 121
   PubMedGoogle Scholar
• Shi M, Sui Y-T, Peskind ER, et al. Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimer’s Dis. 2011;27(2):299–305.
   PubMed Web of Science ®Google Scholar
• Ashton NJ, Ide M, Schöll M, et al. No association of salivary total tau concentration with Alzheimer’s disease. Neurobiol Aging. 2018;70:125–127.
   PubMed Web of Science ®Google Scholar
• Kehoe EG, McNulty JP, Mullins PG, et al. Advances in MRI biomarkers for the diagnosis of Alzheimer’s disease [Internet]. Biomark Med Future Med Ltd. 2014;1151–1169. https://www.futuremedicine.com/doi/abs/10.2217/bmm.14.42.
   Google Scholar
• Golebiowski M, Barcikowska M, Pfeffer A Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type. Dement Geriatr Cogn Disord. 1999;10(4):284–288. https://www.karger.com/Article/FullText/17133.
   PubMedGoogle Scholar
• Juottonen K, Laakso MP, Partanen K, et al. Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer's disease. AJNR Am J Neuroradiol. 1999;20(1):139–144.
   PubMedGoogle Scholar
• Trzepacz PT, Yu P, Sun J, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia. Neurobiology of Aging. 2014;35(1):143–151.
   PubMedGoogle Scholar
• Roe JM, Vidal-Piñeiro D, Sørensen Ø, et al. Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease. Nat Commun. 2021;12(1):1–11. 121
   PubMedGoogle Scholar
• Planche V, Bouteloup V, Mangin J-F, et al. Alzheimer’s disease brain atrophy subtypes are associated with incident dementia in subjective cognitive complaint and mild cognitive impairment. Alzheimer’s Dement. 2020;16(S5):e039861.
   Google Scholar
• Mofrad SA, Lundervold AJ, Vik A, et al. Cognitive and MRI trajectories for prediction of Alzheimer’s disease. Sci Rep. 2021;11:1–10. 111: https://www.nature.com/articles/s41598-020-78095-7
   PubMedGoogle Scholar
• Ford J, Kafetsouli D, Wilson H, et al. At a glance: an update on neuroimaging and retinal imaging in Alzheimer’s disease and related research. J Prev Alzheimer’s Dis. 2022;9:67–76. 91: https://link.springer.com/article/10.14283/jpad.2022.7
   PubMedGoogle Scholar
• Behfar Q, Behfar SK, von Reutern B, et al. Graph theory analysis reveals resting-state compensatory mechanisms in healthy aging and prodromal Alzheimer’s disease. Front Aging Neurosci. 2020;12:1–13.
   PubMedGoogle Scholar
• Prakash RS, McKenna MR, Gbadeyan O, et al. A whole-brain functional connectivity model of Alzheimer’s disease pathology. medRxiv [Internet]. 2021 [cited 2022 Mar 19];2021.01.13.21249597. Available from: https://www.medrxiv.org/content/10.1101/2021.01.13.21249597v1.
   Google Scholar
• Badji A, Westman E. Cerebrovascular pathology in Alzheimer’s disease: hopes and gaps. Psychiatry Res Neuroimaging. 2020;306:111184.
   PubMedGoogle Scholar
• Tubi MA, Feingold FW, Kothapalli D, et al. White matter hyperintensities and their relationship to cognition: effects of segmentation algorithm. Neuroimage. 2020;206:116327.
   PubMedGoogle Scholar
• Kuhn E, Perrotin A, and Tomadesso C, et al. Subjective cognitive decline: opposite links to neurodegeneration across the Alzheimer’s continuum. Brain Commun. 2021;3(3). DOI: 10.1093/braincomms/fcab199.
   Google Scholar
• Villa C, Lavitrano M, Salvatore E, et al. Molecular and imaging biomarkers in Alzheimer’s disease: a focus on recent insights. J Pers Med. 2020;10(3):1–32.
   Google Scholar
• Forgrave LM, Ma M, Best JR, et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimer’s Dement: Diagn Assess Dis Monit. 2019;730–743.
   PubMedGoogle Scholar
• Osborn KE, Khan OA, Kresge HA, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2019;11:700–709. /pmc/articles/PMC6827361/.
   PubMedGoogle Scholar
• Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid Status. JAMA Neurol. 2019;76(9):1060–1069.
   PubMed Web of Science ®Google Scholar
• Marizzoni M, Ferrari C, Babiloni C, et al. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiol Aging. 2020;89:55–62.
   PubMedGoogle Scholar
• Dhiman K, Gupta VB, Villemagne VL, et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2020;12: /pmc/articles/PMC7085283/.
   PubMedGoogle Scholar
• Mattsson N, Andreasson U, Zetterberg H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2017;74(5):557–566.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–140.
   PubMed Web of Science ®Google Scholar
• Rojas JC, Bang J, Lobach I V, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90(4):e273–e281.
   PubMed Web of Science ®Google Scholar
• Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25(2):277–283. Internet
   PubMed Web of Science ®Google Scholar
• Sánchez-Valle R, Heslegrave A, Foiani MS, et al. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. Alzheimer’s Res Ther. 2018;10:1–6. 101: https://alzres.biomedcentral.com/articles/10.1186/s13195-018-0439-y
   PubMedGoogle Scholar
• Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89(21):2167–2175.
   PubMedGoogle Scholar
• Y-n O, Xu W, J-q L, et al. FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11(1):57.
   PubMedGoogle Scholar
• Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62(11):1728–1733.
   PubMedGoogle Scholar
• Chen M-K, Mecca AP, Naganawa M, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215–1224.
   PubMedGoogle Scholar
• Constantinescu CC, Tresse C, Zheng M, et al. Development and in Vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol. 2018;213(21):509–518. https://link.springer.com/article/10.1007/s11307-018-1260-5
   Google Scholar
• Li S, Cai Z, Zhang W, et al. Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). Eur J Nucl Med Mol Imaging. 2019;46(9):1952–1965. 469
   PubMedGoogle Scholar
• Schmidt FM, Mergl R, Stach B, et al. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer’s disease. Neurosci Lett. 2014;570:81–85.
   PubMedGoogle Scholar
• Llorens F, Schmitz M, Knipper T, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease show different but partially overlapping profile compared to vascular dementia. Front Aging Neurosci. 2017;9:289.
   PubMedGoogle Scholar
• Lista S, Hampel H Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease [Internet]. Expert Rev. Neurother. Taylor and Francis Ltd; 2017.p.4757. https://www.tandfonline.com/doi/abs/10.1080/14737175.2016.1204234.
   Google Scholar
• Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimer’s Dement. 2015;11(10):1180–1190.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H The past and the future of Alzheimer’s disease fluid biomarkers [Internet]. J. Alzheimer’s Dis. IOS Press; 2018. p. 1125–1140. http://post-test.com/JAD-9.
   Google Scholar
• Kvartsberg H, Lashley T, Murray CE, et al. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease. Acta Neuropathol. 2019;137(1):89–102.
   PubMedGoogle Scholar
• Willemse EAJ, De Vos A, Herries EM, et al. Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: an assay comparison study. Clin Chem. 2018;64(6):927–937.
   PubMed Web of Science ®Google Scholar
• Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain. 2015;138(11):3373–3385.
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829–835.
   PubMed Web of Science ®Google Scholar
• Brinkmalm A, Brinkmalm G, Honer WG, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener. 2014;9:1–13. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-9-53.
   PubMedGoogle Scholar
• Davidsson P, Blennow K Neurochemical dissection of synaptic pathology in Alzheimer’s disease. Int Psychogeriatrics. 1998;10(1):11–23. https://pubmed.ncbi.nlm.nih.gov/9629521/.
   PubMedGoogle Scholar
• Clarke MTM, Brinkmalm A, Foiani MS, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia. Alzheimer’s res ther 111. 2019;11:1–9. https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0564-2
   Google Scholar
• Öhrfelt A, Brinkmalm A, Dumurgier J, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease. Alzheimer’s Res Ther. 2016;8:1–10. https://pubmed.ncbi.nlm.nih.gov/27716408/.
   PubMedGoogle Scholar
• Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener. 2018;1–16. DOI: 10.1186/s13024-018-0298-9
   PubMedGoogle Scholar
• Atagi Y, Liu -C-C, Painter MM, et al. Apolipoprotein E Is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2) *. J Biol Chem. 2015;290(43):26043–26050.
   PubMed Web of Science ®Google Scholar
• Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22(2):191–204. 222
   PubMedGoogle Scholar
• Heslegrave A, Heywood W, Paterson R, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Mol Neurodegener. 2016;11(1). DOI: 10.1186/s13024-016-0071-x.
   Google Scholar
• Suárez-Calvet M, Caballero MÁA, Kleinberger G, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178–369ra178.
   PubMed Web of Science ®Google Scholar
• Piccio L, Deming Y, Del-Águila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925–933.
   PubMed Web of Science ®Google Scholar
• Liu D, Cao B, Zhao Y, et al. Soluble TREM2 changes during the clinical course of Alzheimer’s disease: a meta-analysis. Neurosci Lett. 2018;686:10–16.
   PubMed Web of Science ®Google Scholar
• Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14(1):1–14. 141
   PubMedGoogle Scholar
• Piccio L, Buonsanti C, Cella M, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(11):3081–3091.
   PubMedGoogle Scholar
• Henjum K, Quist-Paulsen E, Zetterberg H, et al. CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau. J Neuroinflammation. 2018;15(1):1–15. 151.
   PubMedGoogle Scholar
• Ishiki A, Kamada M, Kawamura Y, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258–261.
   PubMedGoogle Scholar
• Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68(10):903–912.
   PubMed Web of Science ®Google Scholar
• Lleó A, Alcolea D, Martínez-Lage P, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimer’s Dement. 2019;15(6):742–753.
   PubMed Web of Science ®Google Scholar
• Kester MI, Teunissen CE, Sutphen C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimer’s Res Ther 71. 2015;7:1–9. https://alzres.biomedcentral.com/articles/10.1186/s13195-015-0142-1.
   PubMedGoogle Scholar
• Scarf AM, Kassiou M The translocator protein. J Nucl Med. 2011;52(5):677–680. https://jnm.snmjournals.org/content/52/5/677.
   PubMed Web of Science ®Google Scholar
• Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain. 2017;140(7):2002–2011.
   PubMedGoogle Scholar
• Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology. 2007;68(7):501–508.
   PubMedGoogle Scholar
• Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28.2012;32:1–5.
   Google Scholar
• Carro E, Bartolomé F, Bermejo-Pareja F, et al. Early diagnosis of mild cognitive impairment and Alzheimer’s disease based on salivary lactoferrin. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2017;8:131. /pmc/articles/PMC5470603/.
   PubMedGoogle Scholar
• Shen X-N, Niu L-D, Wang Y-J, et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90(5):590–598.
   PubMedGoogle Scholar
• Angelopoulou E, Paudel YN, Shaikh MF, et al. Flotillin: a promising biomarker for Alzheimer’s disease. J Pers Med. 2020;10(2):20.
   Google Scholar
• Abdullah M, Kimura N, Akatsu H, et al. Flotillin is a novel diagnostic blood marker of Alzheimer’s disease. J Alzheimer’s Dis. 2019;72(4):1165–1176.
   PubMedGoogle Scholar
• Zengi O, Karakas A, Ergun U, et al. Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease. Clin Chem Lab Med. 2012;50(3):529–534.
   Web of Science ®Google Scholar
• Increased 8,12‐iso‐iPF2α‐VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity - Praticò - 2000 - Annals of neurology - Wiley Online Library [Internet]. cited 2021 Aug 4]. Available from 2021 Aug 4: https://onlinelibrary.wiley.com/doi/abs/10.1002/1531-8249%28200011%2948%3A5%3C809%3A%3AAID-ANA19%3E3.0.CO%3B2-9?sid=nlm%3Apubmed.
   Google Scholar
• Zhang J, Zhang C-H, R-j L, et al. Accuracy of urinary AD7c-NTP for Diagnosing Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimer’s Dis. 2014;40(1):153–159.
   PubMedGoogle Scholar
• Yao F, Hong X, Li S, et al. Urine-based biomarkers for Alzheimer’s disease identified through coupling computational and experimental methods. J Alzheimer’s Dis. 2018;65(2):421–431.
   PubMedGoogle Scholar
• Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–2193.
   PubMedGoogle Scholar
• James BD, Wilson RS, Boyle PA, et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain. 2016;139(11):2983.
   PubMedGoogle Scholar
• Mollenhauer B, El-Agnaf OM, Marcus K, et al. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers in Medicine. 2010;4(5): 683–689.
   PubMedGoogle Scholar
• Paciotti S, Bellomo G, Gatticchi L, et al. Are we ready for detecting α-synuclein prone to aggregation in patients? The case of “protein-misfolding cyclic amplification” and “real-time quaking-induced conversion” as diagnostic tools. Front Neurol. 2018; 415.
   PubMedGoogle Scholar
• Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163–172.
   PubMed Web of Science ®Google Scholar
• Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther. 2017 61;6(S1):15–24.
   PubMedGoogle Scholar
• Guzman-Martinez L, Maccioni RB, Farías GA, et al. Biomarkers for Alzheimer’s disease. Curr Alzheimer Res. 2019;16(6):518–528.
   PubMed Web of Science ®Google Scholar
• Henriksen K, O’Bryant SE, Hampel H, et al. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimer’s Dement. 2014;10(1):115–131.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer ’ s disease. 2019;1:1–7.
   Google Scholar
• Kim K, Kim MJ, and Kim DW, et al. Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma. Nat Commun. 2020;11(1):1–9. 111
   PubMed Web of Science ®Google Scholar
• Ashton NJ, Schöll M, Heurling K, et al. Update on biomarkers for amyloid pathology in Alzheimer’s disease. Biomarkers in Medicine. 2018;12(7): 799–812.
   PubMedGoogle Scholar
• Spielmann N, Wong D Saliva: diagnostics and therapeutic perspectives. Oral Dis. 2011;17(4):345–354. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1601-0825.2010.01773.x.
   PubMed Web of Science ®Google Scholar
• Goldstein LE, Muffat JA, Cherny RA, et al. Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet. 2003;361(9365):1258–1265.
   PubMed Web of Science ®Google Scholar
• Kalló G, Emri M, Varga Z, et al. Changes in the chemical barrier composition of tears in Alzheimer’s disease reveal potential tear diagnostic biomarkers. PLoS One. 2016;11(6):e0158000.
   PubMed Web of Science ®Google Scholar
• Ausó E, Gómez-Vicente V, and Esquiva G. Biomarkers for Alzheimer’s disease early diagnosis. J Pers Med. 2020;10(3):1–27.
   Web of Science ®Google Scholar
• Navas-Carrillo D, Ríos A, Rodríguez JM, et al. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings. Biochim Biophys Acta - Rev Cancer. 2014;1846(2):468–476.
   Google Scholar
• Kozomara A, Birgaoanu M, Griffiths-Jones S miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–D162. https://academic.oup.com/nar/article/47/D1/D155/5179337.
   PubMed Web of Science ®Google Scholar
• Long JM, Lahiri DK. MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun. 2011;404(4):889–895.
   PubMed Web of Science ®Google Scholar
• Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17):6415–6420.
   PubMed Web of Science ®Google Scholar
• Boissonneault V, Plante I, Rivest S, et al. MicroRNA-298 and microRNA-328 regulate expression of mouse β-amyloid precursor protein-converting enzyme 1 *. J Biol Chem. 2009;284(4):1971–1981.
   PubMed Web of Science ®Google Scholar
• Tan L, Yu JT, Hu N, et al. Non-coding RNAs in Alzheimer’s disease. Molecular Neurobiology Mol Neurobiol . 2012;47(1):382–393. Available from: https://link.springer.com/article/10.1007/s12035-012-8359-5.
   PubMedGoogle Scholar
• Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus.Neuroreport. 2007;18(3):297–300.
   PubMed Web of Science ®Google Scholar
• Kumar S, Vijayan M, Reddy PH MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum Mol Genet. 2017;26(19):3808–3822. https://academic.oup.com/hmg/article/26/19/3808/3976567.
   PubMed Web of Science ®Google Scholar
• Kiko T, Nakagawa K, Tsuduki T, et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimer’s Dis. 2014;39(2):253–259.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu J, Wang Q, et al. MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB. Front Pharmacol. 2019;10:806.
   PubMed Web of Science ®Google Scholar
• Navas-Carrillo D, Rivera-Caravaca JM, Sampedro-Andrada A, et al. Novel biomarkers in Alzheimer’s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites. Crit Rev Clin Lab Sci. 2021;58(3):167–179.
   PubMed Web of Science ®Google Scholar
• Ansari A, Maffioletti E, Milanesi E, et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging. 2019;82:102–109.
   PubMed Web of Science ®Google Scholar
• Herrera-Espejo S, Santos-Zorrozua B, Álvarez-González P, et al. A systematic review of microRNA expression as biomarker of late-onset Alzheimer’s disease. Mol Neurobiol. 2019;56(12):8376–8391. Available from
   PubMed Web of Science ®Google Scholar
• Takousis P, Sadlon A, Schulz J, et al. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid. Alzheimer’s Dement. 2019;15(11):1468–1477.
   PubMed Web of Science ®Google Scholar
• Siedlecki-Wullich D, Català-Solsona J, Fábregas C, et al. Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease. Alzheimer’s Res Ther. 2019;11:1–11. https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0501-4.
   PubMedGoogle Scholar
• Rufino-Ramos D, Albuquerque PR, Carmona V, et al. Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release. 2017;262:247–258.
   PubMed Web of Science ®Google Scholar
• Lee S, Mankhong S, Kang JH Extracellular vesicle as a source of Alzheimer’s biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20(7):1728. https://www.mdpi.com/1422-0067/20/7/1728/htm.
   PubMed Web of Science ®Google Scholar
• Chiasserini D, Van Weering JRT, Piersma SR, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J Proteomics. 2014;106:191–204.
   PubMed Web of Science ®Google Scholar
• Muraoka S, Jedrychowski MP, Yanamandra K, et al. Proteomic profiling of extracellular vesicles derived from Cerebrospinal fluid of Alzheimer’s disease patients: a pilot study. Cells. 2020;9(9):1959.
   Web of Science ®Google Scholar
• Cilento EM, Jin L, Stewart T, et al. Mass spectrometry: a platform for biomarker discovery and validation for Alzheimer’s and Parkinson’s diseases. J Neurochem. 2019;151(4):397.
   PubMed Web of Science ®Google Scholar
• Ringman JM, Schulman H, Becker C, et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol. 2012;69(1):96–104.
   PubMedGoogle Scholar
• Hendrickson RC, Lee AYH, Song Q, et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer’s disease in human cerebrospinal fluid. PLoS One. 2015;10(8):e0135365.
   PubMed Web of Science ®Google Scholar
• Hölttä M, Minthon L, Hansson O, et al. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer’s disease. J Proteome Res. 2015;14(2):654–663.
   PubMed Web of Science ®Google Scholar
• Wildsmith KR, Schauer SP, Smith AM, et al. Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener. 2014;9(1):22.
   PubMedGoogle Scholar
• Bader JM, Geyer PE, Müller JB, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer’s disease. Mol Syst Biol. 2020;16(6):e9356.
   PubMed Web of Science ®Google Scholar
• Wang H, Dey KK, Chen PC, et al. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease. Mol Neurodegener. 2020;15(1):1–20.
   PubMed Web of Science ®Google Scholar
• Zhou M, Haque RU, Dammer EB, et al. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease. Clin Proteomics. 2020;17(1):1–14.
   PubMedGoogle Scholar
• Mapstone M, Lin F, Nalls MA, et al. What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer’s disease. Neurobiol Aging. 2017;51:148–155.
   PubMed Web of Science ®Google Scholar
• Hurtado MO, Kohler I, De Lange ECM. Next-generation biomarker discovery in Alzheimer’s disease using metabolomics – from animal to human studies. Bioanalysis. 2018;10(18):1525–1546.
   PubMed Web of Science ®Google Scholar
• Chouraki V, Preis SR, Yang Q, et al. Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimer’s Dement. 2017;13(12):1327–1336.
   PubMed Web of Science ®Google Scholar
• de Leeuw FA, Peeters CFW, Kester MI, et al. Blood-based metabolic signatures in Alzheimer’s disease. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2017;8:196. /pmc/articles/PMC5607205/.
   PubMedGoogle Scholar
• John-Williams L S, Blach C, Toledo JB, et al. Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Sci Data. 2017;4. /pmc/articles/PMC5644370/.
   Google Scholar
• Graham SF, Chevallier OP, Elliott CT, et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer’s disease. PLoS One. 2015;10(3):e0119452.
   PubMed Web of Science ®Google Scholar
• Sun C, Gao M, Wang F, et al. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS. Biomed Chromatogr. 2020;34(9):e4875.
   PubMedGoogle Scholar
• Mahajan UV, Varma VR, Griswold ME, et al. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: a targeted metabolomic and transcriptomic study. PLOS Med. 2020;17(1):e1003012.
   PubMed Web of Science ®Google Scholar
• Islam J, and Zhang Y A novel deep learning based multi-class classification method for Alzheimer’s disease detection using brain MRI data. Lect Notes Comput Sci (including Subser Lect Notes Artif Intell Lect Notes Bioinformatics). 2017 10654 LNAI:213–222. DOI: 10.1007/978-3-319-70772-3_20.
   Google Scholar
• Katako A, Shelton P, Goertzen AL, et al. Machine learning identified an Alzheimer’s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson’s disease dementia. Sci Rep. 2018;81 8:1–13.https://www.nature.com/articles/s41598-018-31653-6.
   PubMedGoogle Scholar
• Sarraf S, Tofighi G, Org S Classification of Alzheimer’s disease structural MRI data by deep learning convolutional neural networks. 2016 cited 2022 Apr 11]; Available from 2022 Apr 11: https://arxiv.org/abs/1607.06583v2.
   Google Scholar
• Mahmood R, and Ghimire B. Automatic detection and classification of Alzheimer’s disease from MRI scans using principal component analysis and artificial neural networks. Int Conf Syst Signals Image Process. 2013;133–137. DOI: 10.1109/IWSSIP.2013.6623471.
   Google Scholar
• Davatzikos C, Resnick SM, Wu X, et al. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage. 2008;41(4):1220–1227.
   PubMed Web of Science ®Google Scholar
• Kautzky A, Seiger R, Hahn A, et al. Prediction of autopsy verified neuropathological change of Alzheimer’s disease using machine learning and MRI. Front Aging Neurosci. 2018;10:406.
   PubMedGoogle Scholar
• Ahmed OB, Benois-Pineau J, Allard M, et al. Recognition of Alzheimer’s disease and mild cognitive impairment with multimodal image-derived biomarkers and multiple Kernel learning. Neurocomputing. 2017;220:98–110.
   Web of Science ®Google Scholar
• Jabason E, Omair Ahmad M, Swamy MNS. Deep structural and clinical feature learning for semi-supervised multiclass prediction of Alzheimer’s disease. Midwest Symp Circuits Syst. 2019;2018(August):791–794.
   Google Scholar
• Lee SH, Bachman AH, Yu D, et al. Predicting progression from mild cognitive impairment to Alzheimer’s disease using longitudinal callosal atrophy. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2016;2:68. /pmc/articles/PMC4879655/.
   PubMedGoogle Scholar
• Salvatore C, Cerasa A, Battista P, et al. Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer’s disease: a machine learning approach. Front Neurosci. 2015;9:307.
   PubMed Web of Science ®Google Scholar
• Plant C, Teipel SJ, Oswald A, et al. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer’s disease. Neuroimage. 2010;50(1):162–174.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang D, Shen D. Relationship induced multi-template learning for diagnosis of Alzheimer’s disease and mild cognitive impairment. IEEE Trans Med Imaging. 2016;35(6):1463–1474.
   PubMed Web of Science ®Google Scholar
• Lu D, Popuri K, Ding GW, et al. Multimodal and multiscale deep neural networks for the early diagnosis of Alzheimer’s disease using structural MR and FDG-PET images. Sci Rep. 81 2018;8:1–13.https://www.nature.com/articles/s41598-018-22871-z.
   PubMed Web of Science ®Google Scholar
• Yan T, Wang Y, Weng Z, et al. Early-stage identification and pathological development of Alzheimer’s disease using multimodal MRI. J Alzheimer’s Dis. 2019;68(3):1013–1027.
   PubMedGoogle Scholar
• Lebedev AV, Westman E, Van Westen GJP, et al. Random Forest ensembles for detection and prediction of Alzheimer’s disease with a good between-cohort robustness. NeuroImage Clin. 2014;6:115–125.
   PubMedGoogle Scholar
• Cassani R, Falk TH, Fraga FJ, et al. Towards automated electroencephalography-based Alzheimer’s disease diagnosis using portable low-density devices. Biomed Signal Process Control. 2017;33:261–271.
   Google Scholar
• Mamani GQ, Fraga FJ, Tavares G, et al. EEG-based biomarkers on working memory tasks for early diagnosis of Alzheimer’s disease and mild cognitive impairment. 2017 IEEE Healthc Innov Point Care Technol HI-POCT 2017. 2017;2017-December:237–240.
   Google Scholar
• Trambaiolli LR, Spolaôr N, Lorena AC, et al. Feature selection before EEG classification supports the diagnosis of Alzheimer’s disease. Clin Neurophysiol. 2017;128(10):2058–2067.
   PubMedGoogle Scholar
• Jeong DH, Do KY, Song IU, et al. Wavelet energy and Wavelet coherence as EEG biomarkers for the Diagnosis of Parkinson’s disease-related Dementia and Alzheimer’s disease. Entropy. 2016. 2015 https://www.mdpi.com/1099-4300/18/1/8/htm.
   Google Scholar
• Dauwan M, van der Zande JJ, van Dellen E, et al. Random forest to differentiate dementia with Lewy bodies from Alzheimer’s disease. Alzheimer’s Dement Diagnosis Assess Dis Monit. 2016;4:99. /pmc/articles/PMC5050257/.
   PubMedGoogle Scholar
• McBride JC, Zhao X, Munro NB, et al. Sugihara causality analysis of scalp EEG for detection of early Alzheimer’s disease. Neuroimage (Amst). 2015;7:258. /pmc/articles/PMC4300018/.
   PubMedGoogle Scholar
• Grassi M, Perna G, Caldirola D, et al. A clinically-translatable machine learning algorithm for the prediction of Alzheimer’s disease conversion in individuals with mild and premild cognitive impairment. J Alzheimer’s Dis. 2018;61(4):1555–1573.
   PubMedGoogle Scholar
• Multimodal monitoring of Parkinson’s and Alzheimer’s patients using the ICT4LIFE platform — Maastricht University [Internet]. cited 2022 Apr 11]. Available from 2022 Apr 11: https://cris.maastrichtuniversity.nl/en/publications/multimodal-monitoring-of-parkinsons-and-alzheimers-patients-using.
   Google Scholar
• Colloby SJ, Cromarty RA, Peraza LR, et al. Multimodal EEG-MRI in the differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Psychiatr Res. 2016;78:48–55.
   PubMedGoogle Scholar
• Fraser KC, Fors KL, and Kokkinakis D, et al. An analysis of eye-movements during reading for the detection of mild cognitive impairment. EMNLP - Conf empir methods nat lang process proc. 2017:1016–1026. DOI:10.18653/v1/D17-1107.
   Google Scholar
• Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–663.
   PubMed Web of Science ®Google Scholar
• Janeiro MH, Ardanaz CG, and Sola-sevilla N, et al. Biomarkers in Alzheimer ’ s disease. Avances en Medicina de Laboratorio. 2021;2:27–37.
   Google Scholar
• Schindler SE, Bateman RJ. Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia. Nat Aging. 2021;1(1):26–28.
   Google Scholar
• Snyder PJ, Alber J, Alt C, et al. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimer’s Dement. 2021;17(1):103–111.
   PubMedGoogle Scholar